Galectin Therapeutics GALT
NASDAQ GALT
$3.38 -0.05 (-1.31%)
As of: Oct 21, 2026 · 3:54 PM EDT

Galectin Therapeutics (GALT) Debt Ratio (2024 - 2026)

Updated

Galectin Therapeutics' (GALT) Debt Ratio stood at 2.23 in Q2 2026.

Analysis

Galectin Therapeutics (GALT) Debt Ratio (2024 - 2026) Analysis & Trends

For FY2024, Galectin Therapeutics' Debt Ratio came in at 1.21.

  • The Q2 2026 figure is the lowest quarterly Debt Ratio since Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,135.76 Bn 1,104.34 Bn 19.71 Bn 0.39
2 Johnson & Johnson 619.07 Bn 537.60 Bn 17.26 Bn 0.24
3 AbbVie 503.11 Bn 476.22 Bn 12.70 Bn 0.52
4 Merck 370.23 Bn 324.61 Bn 12.21 Bn 0.42
5 Novartis Ag 298.76 Bn 262.75 Bn 11.24 Bn 0.08
6 Astrazeneca 261.14 Bn 234.83 Bn 12.86 Bn 0.28
7 Amgen 237.54 Bn 192.94 Bn 7.24 Bn 0.60
8 Gilead Sciences 191.65 Bn 165.84 Bn 6.22 Bn 0.53
9 Pfizer 170.26 Bn 116.90 Bn 10.94 Bn 0.31
10 Galectin Therapeutics 222.66 Mn 166.00 Mn - 2.23
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.23
Sep 30, 2025 2.53
Mar 31, 2025 2.23
Dec 31, 2024 1.21
Sep 30, 2024 0.36
API Access

Galectin Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=GALT&period=max&api_key=YOUR_API_KEY